Literature DB >> 24735183

Macrolide, lincosamide, and streptogramin B resistance in lipophilic Corynebacteria inhabiting healthy human skin.

Magdalena Szemraj1, Anna Kwaszewska, Renata Pawlak, Eligia M Szewczyk.   

Abstract

Corynebacteria exist as part of human skin microbiota. However, under some circumstances, they can cause opportunistic infections. The subject of the study was to examine the macrolide-lincosamide-streptogramin B (MLSB) antibiotic resistance in 99 lipophilic strains of Corynebacterium genus isolated from the skin of healthy men. Over 70% of the tested strains were resistant to erythromycin and clindamycin. All of which demonstrated a constitutive type of MLSB resistance mechanism. In all strains, there were being investigated the erm(A), erm(B), erm(C), erm(X), lin(A), msr(A), and mph(C) genes that could be responsible for the different types of resistance to marcolides, lincosamides, and streptogramin B. In all strains with the MLSB resistance phenotype, the erm(X) gene was detected. None of the other tested genes were discovered. Strains harboring the erm(X) gene were identified using a phenotypic method based on numerous biological and biochemical tests. Identification of the chosen strains was compared with the results of API Coryne, MALDI-TOF MS, and 16S rDNA sequencing methods. Only 7 out of the 23 investigated resistant strains provided successful results in all the used methods, showing that identification of this group of bacteria is still a great challenge. The MLSB resistance mechanism was common in most frequently isolated from healthy human skin Corynebacterium tuberculostearicum and Corynebacterium jeikeium strains. This represents a threat as these species are also commonly described as etiological factors of opportunistic infections.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24735183     DOI: 10.1089/mdr.2013.0192

Source DB:  PubMed          Journal:  Microb Drug Resist        ISSN: 1076-6294            Impact factor:   3.431


  7 in total

1.  Antimicrobial Treatment Options for Granulomatous Mastitis Caused by Corynebacterium Species.

Authors:  Hazel C Dobinson; Trevor P Anderson; Stephen T Chambers; Matthew P Doogue; Lois Seaward; Anja M Werno
Journal:  J Clin Microbiol       Date:  2015-07-01       Impact factor: 5.948

Review 2.  Resistance to Macrolide Antibiotics in Public Health Pathogens.

Authors:  Corey Fyfe; Trudy H Grossman; Kathy Kerstein; Joyce Sutcliffe
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

3.  Differences in distribution of MLS antibiotics resistance genes in clinical isolates of staphylococci belonging to species: S. epidermidis, S. hominis, S. haemolyticus, S. simulans and S. warneri.

Authors:  Magdalena Szemraj; Tomasz Czekaj; Jacek Kalisz; Eligia M Szewczyk
Journal:  BMC Microbiol       Date:  2019-06-10       Impact factor: 3.605

4.  Characterization of the human skin resistome and identification of two microbiota cutotypes.

Authors:  Zhiming Li; Jingjing Xia; Liuyiqi Jiang; Yimei Tan; Yitai An; Xingyu Zhu; Jie Ruan; Zhihua Chen; Hefu Zhen; Yanyun Ma; Zhuye Jie; Liang Xiao; Huanming Yang; Jian Wang; Karsten Kristiansen; Xun Xu; Li Jin; Chao Nie; Jean Krutmann; Xiao Liu; Jiucun Wang
Journal:  Microbiome       Date:  2021-02-17       Impact factor: 14.650

5.  Whole genome sequence of a non-toxigenic Corynebacterium diphtheriae strain from a hospital in southeastern China.

Authors:  Guogang Li; Sipei Wang; Sheng Zhao; Yangxiao Zhou; Xinling Pan
Journal:  BMC Genom Data       Date:  2021-10-16

6.  New Gene Responsible for Resistance of Clinical Corynebacteria to Macrolide, Lincosamide and Streptogramin B.

Authors:  Magdalena Szemraj; Anna Kwaszewska; Eligia M Szewczyk
Journal:  Pol J Microbiol       Date:  2018-06-30

7.  Atypical pathogens associated with cardiac implantable electronic device infections.

Authors:  Utkarsh Kohli; Aniruddha Hazra; Ahmed Shahab; Andrew D Beaser; Zaid A Aziz; Gaurav A Upadhyay; Cevher Ozcan; Roderick Tung; Hemal M Nayak
Journal:  Pacing Clin Electrophysiol       Date:  2021-07-26       Impact factor: 1.912

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.